Get the Stockscreener App
21.95
1.79%
-0.40
Enliven Therapeutics Inc stock is traded at $21.95, with a volume of 222.82K.
It is down -1.79% in the last 24 hours and up +3.73% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$22.35
Open:
$22.44
24h Volume:
222.82K
Relative Volume:
0.46
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-11.61
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
-5.96%
1M Performance:
+3.73%
6M Performance:
+0.41%
1Y Performance:
-8.58%
1-Day Range:
$21.80
$22.83
1-Week Range:
$21.38
$24.38
52-Week Range:
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.95 | 1.27B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
What risks could impact Enliven Therapeutics Inc. stock performanceMarket-beating returns - jammulinksnews.com
What drives Enliven Therapeutics Inc. stock priceSky-high profits - PrintWeekIndia
Polis encourages life-sciences companies to move to Colorado - BizWest
Enliven Therapeutics Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - Autocar Professional
What analysts say about Enliven Therapeutics Inc. stockOutstanding investment returns - Autocar Professional
Is Enliven Therapeutics Inc. a good long term investmentTriple-digit growth rates - Autocar Professional
Enliven Therapeutics CSO sells $278k in shares - Investing.com Australia
Enliven Therapeutics CSO sells $278k in shares By Investing.com - Investing.com India
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN
Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - Defense World
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionDaily Price Surge List - Newser
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Will Enliven Therapeutics Inc. stock split in the near futureTop Performing Low Risk Stocks - Newser
Enliven Therapeutics’ Promising CML Treatment: A Study Update - TipRanks
What makes Enliven Therapeutics Inc. stock price move sharplyFree Investment Community - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Enliven Therapeutics CFO Hohl sells $22,655 in shares - Investing.com Australia
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $41.20 - Defense World
Enliven Therapeutics Breaks Above 200-Day Moving AverageBullish for ELVN - Nasdaq
Enliven Therapeutics COO Patel sells shares worth $131950 By Investing.com - Investing.com Canada
Enliven Therapeutics COO Patel sells shares worth $131950 - Investing.com
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):